8VRS
Mucin 16 peptide fused to MBP in complex with 4H11-scFv antibody
Summary for 8VRS
| Entry DOI | 10.2210/pdb8vrs/pdb |
| Related | 8VRR |
| Descriptor | Maltose/maltodextrin-binding periplasmic protein,Mucin-16, 4H11 scFv chain (3 entities in total) |
| Functional Keywords | antibody complex epitope cancer therapy immunotherapy mucins, oncoprotein, oncoprotein-immune system complex, oncoprotein/immune system |
| Biological source | Escherichia coli More |
| Total number of polymer chains | 4 |
| Total formula weight | 142226.87 |
| Authors | Lee, K.,Perry, K.,Yeku, O.O.,Spriggs, D.R. (deposition date: 2024-01-22, release date: 2024-04-03, Last modification date: 2024-11-06) |
| Primary citation | Lee, K.,Perry, K.,Xu, M.,Veillard, I.,Kumar, R.,Rao, T.D.,Rueda, B.R.,Spriggs, D.R.,Yeku, O.O. Structural basis for antibody recognition of the proximal MUC16 ectodomain. J Ovarian Res, 17:41-41, 2024 Cited by PubMed Abstract: Mucin 16 (MUC16) overexpression is linked with cancer progression, metastasis, and therapy resistance in high grade serous ovarian cancer and other malignancies. The cleavage of MUC16 forms independent bimodular fragments, the shed tandem repeat sequence which circulates as a protein bearing the ovarian cancer biomarker (CA125) and a proximal membrane-bound component which is critical in MUC16 oncogenic behavior. A humanized, high affinity antibody targeting the proximal ectodomain represents a potential therapeutic agent against MUC16 with lower antigenic potential and restricted human tissue expression. PubMed: 38374055DOI: 10.1186/s13048-024-01373-9 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.47 Å) |
Structure validation
Download full validation report
